Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 3c

Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint

February 25, 2020 4:16 PM EST

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic dermatitis (AD) in adults. The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population. However, the antipruritic effect of tradipitant was robust in the mild AD study population. Mild AD represents over 60% of the total AD population in the U.S.1, 2 The EPIONE study continued to demonstrate that tradipitant is safe and well-tolerated.

"Although we are disappointed... More

Vanda Pharmaceuticals (VNDA) Halted, News Pending

February 25, 2020 4:03 PM EST

Vanda Pharmaceuticals (NASDAQ: VNDA) Halted, News Pending

... More